Know Labs, INC.: insider trades · United States · SEC (Form 4)

About Know Labs, INC.

Know Labs, Inc. is a United States-based listed company that has traded on the NYSE American and, during a period of market stress and listing remediation, also quoted in the OTC market under the symbol KNWN before resuming NYSE American trading under KNW in 2025, according to SEC filings. For investors, that market context is important: the company is a U.S. micro-cap / small-cap medtech story with a high-risk profile and a history of capital markets volatility. Its headquarters are in Seattle, Washington, United States. Know Labs’ core business is the development of proprietary sensor technology built around radio frequency dielectric spectroscopy, marketed under its Bio-RFID platform. The company’s long-standing flagship ambition is non-invasive measurement of blood glucose, with broader claims that the same sensing platform could eventually identify and measure other analytes. In practical terms, Know Labs is not a diversified commercial medtech company with a mature product franchise; it is primarily a technology development and clinical-validation business working toward a future medical device and related applications. The company was incorporated in Nevada in 1998, and its corporate history reflects a transformation from an older shell/corporate structure into a science-driven diagnostics company. Its filings indicate that the organization has spent years advancing laboratory work, sensor design, machine-learning interpretation, and clinical validation. Management has repeatedly emphasized that the first application of the platform is intended to be a non-invasive glucose-monitoring solution, a segment that sits at the intersection of diabetes care, wearables, and digital health. Recent developments have centered on restructuring the go-to-market strategy and preserving optionality. SEC disclosures in 2025 describe the launch of Know Labs Technology Licensing (KTL), a program designed to license the company’s intellectual property to corporate partners, academic institutions, and research organizations. That move suggests a broader monetization model beyond a single device launch, and it may be particularly relevant for a company facing the high cost and uncertainty of clinical trials and regulatory clearance. From a competitive standpoint, Know Labs operates in one of the most challenging areas of medical technology: non-invasive glucose monitoring. The opportunity is attractive because the addressable market is large and current CGM solutions still involve invasive elements. However, the company must prove technical performance, reproducibility, and clinical utility against well-funded incumbents and alternative sensing approaches. As a result, the investment case is highly binary and depends on successful execution across R&D, regulatory, and commercialization milestones. In summary, Know Labs is best understood as a U.S.-listed emerging diagnostics company with a deep technology angle, a Seattle base, and a strategy anchored in Bio-RFID-based non-invasive sensing. For international equity investors, it represents a speculative but potentially disruptive medtech name whose value is driven less by near-term revenues and more by scientific validation, licensing traction, and progress toward FDA-related milestones.